These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38622139)

  • 21. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
    Myers RM; Devine K; Li Y; Lawrence S; Leahy AB; Liu H; Vernau L; Callahan C; Baniewicz D; Kadauke S; McGuire R; Wertheim GB; Kulikovskaya I; Gonzalez VE; Fraietta JA; DiNofia AM; Hunger SP; Rheingold SR; Aplenc R; June CH; Grupp SA; Wray L; Maude SL
    Blood Adv; 2024 May; 8(9):2182-2192. PubMed ID: 38386999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Laetsch TW; Maude SL; Balduzzi A; Rives S; Bittencourt H; Boyer MW; Buechner J; De Moerloose B; Qayed M; Phillips CL; Pulsipher MA; Hiramatsu H; Tiwari R; Grupp SA
    Leukemia; 2022 Jun; 36(6):1508-1515. PubMed ID: 35422096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Jacoby E; Bielorai B; Hutt D; Itzhaki O; Adam E; Bar D; Besser MJ; Toren A
    Br J Haematol; 2022 May; 197(4):475-481. PubMed ID: 35224724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
    Aldoss I; Shan H; Yang D; Clark MC; Al Malki M; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
    Transplant Cell Ther; 2024 Aug; 30(8):788.e1-788.e9. PubMed ID: 38876428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.
    Ma Y; Zhou H; Zhang J; Zhang Q; Li Y; Xie R; Zhang B; Shen Z; Li P; Liang A; Zhou K; Han L; Hu Y; Xu K; Sang W; Wang X
    Front Immunol; 2024; 15():1448709. PubMed ID: 39399502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].
    Zuo YX; Jia YP; Wu J; Wang JB; Lu AD; Dong LJ; Chang LJ; Zhang LP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):270-275. PubMed ID: 31104436
    [No Abstract]   [Full Text] [Related]  

  • 32. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.
    Wang Y; Xue YJ; Zuo YX; Jia YP; Lu AD; Zeng HM; Zhang LP
    Cancer Res Treat; 2024 Jul; 56(3):945-955. PubMed ID: 38351683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.
    Yang J; He J; Zhang X; Li J; Wang Z; Zhang Y; Qiu L; Wu Q; Sun Z; Ye X; Yin W; Cao W; Shen L; Sersch M; Lu P
    Blood Cancer J; 2022 Jul; 12(7):104. PubMed ID: 35798714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
    Li N; Li H
    J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    Wang T; Tang Y; Cai J; Wan X; Hu S; Lu X; Xie Z; Qiao X; Jiang H; Shao J; Yang F; Ren H; Cao Q; Qian J; Zhang J; An K; Wang J; Luo C; Liang H; Miao Y; Ma Y; Wang X; Ding L; Song L; He H; Shi W; Xiao P; Yang X; Yang J; Li W; Zhu Y; Wang N; Gu L; Chen Q; Tang J; Yang JJ; Cheng C; Leung W; Chen J; Lu J; Li B; Pui CH
    J Clin Oncol; 2023 Mar; 41(9):1670-1683. PubMed ID: 36346962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
    Myers RM; Dolan J; Teachey DT
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.